Psilocybin Shows Promise as Depression Treatment in Early Clinical Trials
Psilocybin, the psychoactive compound in magic mushrooms, is showing therapeutic promise for clinical depression in early research. After decades of restricted research, scientists are now conducting rigorous clinical trials. Johns Hopkins studies found that just two psilocybin doses combined with psychotherapy helped half of participants achieve depression remission for at least one month. The treatment involves synthesized psilocybin in controlled clinical settings with trained supervisors. Yale research on mice revealed psilocybin increases formation of new brain connections by 12% and improves stress-related behaviors. One study suggested psilocybin may be as effective as traditional SSRI antidepressants. The compound appears to work by creating lasting neural connections in brain regions involved in cognition and decision-making, potentially addressing the low synapse density associated with depression.